Can Regeneron’s Odronextamab Stand Out With Better Safety?

Entering Crowded CD20 Bispecific Field

Presentation of diffuse large B-cell lymphoma data at ASH showed low rates of higher-grade cytokine release syndrome and no cases of ICANS.

The Regeneron, Genentech and AbbVie booths at the 2023 ASH conference • Source: Scrip

More from Immuno-oncology

More from Conferences